ABBV-399
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ABBV-399, covering 2025-08-14 to 2026-02-23. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2]